-
公开(公告)号：KR1020100018741A
公开(公告)日：2010-02-18
申请号：KR1020080077386
申请日：2008-08-07
Applicant: 신풍제약주식회사 , 충남대학교산학협력단
IPC: A61K9/08 , A61K31/337 , A61P35/00
CPC classification number: A61K47/10 , A61K9/0019 , A61K31/337 , A61K47/12 , A61K47/14 , A61K47/18 , A61K47/34 , A61K2121/00
Abstract: PURPOSE: An injection composition for anti-cancer which containing docetaxel as an active ingredient is provided ensure bioavailability same as a conventional injection product and low hemolysis. CONSTITUTION: An injection composition contains docetaxel as an active ingredient, glycofurol(tetrahydrofurfuryl alcohol polyethyleneglycolether) or DMA(dimethylaceteamide) as a solubilizing agent, and solutol, acepol, or poroxamer as a surfactant. The weight ratio between solubilizing agent and surfactant is 1:0.5-6. The pH concentration of the injection composition is adjusted at pH 4-6.
Abstract translation: 目的：提供含有多西紫杉醇作为活性成分的抗癌注射用组合物，确保与常规注射产品相同的生物利用度和低溶血性。 构成：注射用组合物含有作为活性成分的多西紫杉醇，作为增溶剂的糖醇（四氢糠醇聚乙二醇醚）或DMA（二甲基乙酰胺），作为表面活性剂的溶剂型，acepol或poroxamer。 增溶剂与表面活性剂的重量比为1:0.5-6。 注射组合物的pH浓度调节至pH 4-6。
-
公开(公告)号：KR100798730B1
公开(公告)日：2008-01-29
申请号：KR1020060052606
申请日：2006-06-12
Applicant: 신풍제약주식회사
Abstract: 본 발명은 활성성분으로서 록소프로펜, 잘토프로펜 또는 이들의 염을 각각 함유하는 서방출성 내부핵층 및 속방출성 외부코팅층을 동시에 포함하는 제어방출성 경구용 제제에 관한 것이다.
본 발명에 의해 약물의 체내 방출을 이중으로 제어하게 되면, 속방출성 외부코팅층에 함유된 활성약물이 신속하게 혈중농도를 높이고 서방출성 내부핵층에서 활성약물이 서서히 방출되어 장시간 치료적으로 유용한 혈중농도를 유지시키는 효과가 있다.
록소프로펜, 잘토프로펜, 서방출성, 속방출성-
公开(公告)号：KR100623322B1
公开(公告)日：2006-09-19
申请号：KR1020040088413
申请日：2004-11-02
Applicant: 신풍제약주식회사
IPC: A61K31/357
CPC classification number: A61K31/357 , A61K31/4375 , Y02A50/411 , A61K2300/00
Abstract: 본 발명은 약제학적으로 허용되는 담체와 함께, 유효성분으로서 알테미시닌(artemisinine) 또는 그의 유도체 및 피로나리딘(pyronaridine) 또는 그의 염을 포함하는, 경구투여용 항말라리아 제제에 관한 것이다.
-
Patent Agency Ranking
公开(公告)号：KR100679166B1
公开(公告)日：2007-02-06
申请号：KR1020050093008
申请日：2005-10-04
Applicant: 신풍제약주식회사
IPC: A61K9/16 , A61K31/403
Abstract: A pharmaceutical composition comprising ramipril is provided to show excellent stability against mechanical stress by granulation with mannitol solution. And a method for preparing a pharmaceutical formulation comprising stabilized ramipril is provided to simplify the preparation process, thereby obtaining the ramipril containing formulation within short period of time and maintaining the stability of the formulation for a long time. The pharmaceutical composition is characterized in that ramipril as an active ingredient is granulated with mannitol solution. In the composition, the weight ratio of the ramipril to mannitol is 1:0.25-1. The pharmaceutical oral formulation comprises the pharmaceutical composition and a pharmaceutically acceptable excipient.
Abstract translation: 提供包含雷米普利的药物组合物，以通过用甘露糖醇溶液造粒显示优异的抗机械应激稳定性。 并且提供了一种用于制备包含稳定的雷米普利的药物制剂的方法，以简化制备过程，从而在短时间内获得含有雷米普利的制剂并长时间保持制剂的稳定性。 该药物组合物的特征在于作为活性成分的雷米普利与甘露醇溶液一起造粒。 在该组合物中，雷米普利与甘露糖醇的重量比为1:0.25-1。 药物口服制剂包含药物组合物和药学上可接受的赋形剂。
-
公开(公告)号：KR1020100057423A
公开(公告)日：2010-05-31
申请号：KR1020080116461
申请日：2008-11-21
Applicant: 신풍제약주식회사
IPC: A61K47/48 , A61K31/192 , A61K47/06
CPC classification number: A61K31/192 , A61K9/0053 , A61K47/02 , A61K47/183
Abstract: PURPOSE: A method for preparing dexibuprofen salt and a pharmaceutical composition for oral administration containing the same are provided to enhance release rate and to reduce side effect. CONSTITUTION: A method for preparing a dexibuprofen salt comprises: a step of dissolving dexibuprofen and inorganic base or organic base in two kinds of more polar solvent; a step of adding acetone to crystallize; and a step of drying crystal. The inorganic base or organic base is arginine, lysine, histidine, ornithine, NH4OH, NaOH, or KOH. A pharmaceutical composition contains the dexibuprofen salt and pharmaceutically acceptable carrier. A pharmaceutical composition for oral administration is used in the form of tablet, capsule, granule, pill, or liquid.
Abstract translation: 目的：提供一种制备右旋布洛芬盐的方法和含有这些组合物的用于口服给药的药物组合物以提高释放速率并降低副作用。 构成：一种制备右布洛芬盐的方法，其特征在于，将二苯丙酮酸和无机碱或有机碱溶解在两种极性较大的溶剂中的步骤; 加入丙酮结晶的步骤; 以及干燥晶体的步骤。 无机碱或有机碱是精氨酸，赖氨酸，组氨酸，鸟氨酸，NH 4 OH，NaOH或KOH。 药物组合物含有对映布洛芬盐和药学上可接受的载体。 用于口服给药的药物组合物以片剂，胶囊剂，颗粒剂，丸剂或液体的形式使用。
-
公开(公告)号：KR1020070118444A
公开(公告)日：2007-12-17
申请号：KR1020060052606
申请日：2006-06-12
Applicant: 신풍제약주식회사
CPC classification number: A61K9/2893 , A61K9/2853 , A61K9/286 , A61K9/2866 , A61K31/192 , A61K31/38
Abstract: A controlled-release formulation containing loxoprofen or zaltoprofen is provided to maintain effective concentration of drugs in blood for a long period of time by rapidly increasing blood concentration of active drug in an outer coating layer and slowly releasing the active drug in an inner core layer, thereby reducing an administration time. A controlled-release formulation contains a sustained-release inner core layer and a fast-release outer coating layer containing loxoprofen, zaltoprofen or its salts, respectively, wherein the sustained-release inner core layer contains an active ingredient and a matrix-forming agent and is coated by an enteric coating material, and the fast-release outer coating layer contains an active ingredient and strong disintegrant. The enteric coating material is cellulose ester derivatives, cellulose ether or acryl resin.
Abstract translation: 提供含有洛索洛芬或扎洛芬的控制释放制剂，以通过快速增加外部涂层中的活性药物的血液浓度并缓慢释放内核层中的活性药物来长时间维持药物在血液中的有效浓度， 从而减少给药时间。 缓释制剂包含分别含有洛索洛芬，唑洛芬或其盐的缓释内芯层和快速释放外涂层，其中缓释内芯层含有活性成分和基质形成剂， 被肠溶衣材料包覆，快速释放外涂层含有活性成分和强崩解剂。 肠溶衣材料是纤维素酯衍生物，纤维素醚或丙烯酸树脂。
-
公开(公告)号：KR1020060039286A
公开(公告)日：2006-05-08
申请号：KR1020040088413
申请日：2004-11-02
Applicant: 신풍제약주식회사
IPC: A61K31/357
CPC classification number: A61K31/357 , A61K31/4375 , Y02A50/411 , A61K2300/00
Abstract: The present invention relates to an orally administrable antimalarial combined preparation containing artemisinine or its derivatives, and pyronaridine or its salts, as active ingredients, with pharmaceutically acceptable carriers, and to preparation process thereof.
-
公开(公告)号：KR1020090059017A
公开(公告)日：2009-06-10
申请号：KR1020080020870
申请日：2008-03-06
Applicant: 신풍제약주식회사
IPC: A61K31/216 , A61K31/222 , A61K31/255
Abstract: A pharmaceutical composition for treating liver disease and improving liver function is provided to enhance the treatment effect of liver disease by mixing two kinds of antioxidant. A pharmaceutical composition for treating liver disease and improving liver function comprises biphenyl methyl dicarboxylate and arginine thiozolidine carboxylate in a weight ratio of 1-25:1-200 as active ingredients. The pharmaceutical composition contains 25mg of biphenyl methyl dicarboxylate and 200mg of arginine thiozolidine carboxylate. The pharmaceutical composition further comprises at least one of pharmaceutically allowable carrier. The composition is used in a form of tablet, capsule or suspension.
Abstract translation: 提供一种治疗肝脏疾病和改善肝功能的药物组合物，通过混合两种抗氧化剂来提高肝脏疾病的治疗效果。 用于治疗肝脏疾病和改善肝功能的药物组合物包括重量比为1-25：1-200的联苯甲基二羧酸酯和精氨酸硫唑烷羧酸盐作为活性成分。 药物组合物含有25mg联苯甲基二羧酸酯和200mg精氨酸硫唑烷羧酸盐。 药物组合物还包含药学上可允许的载体中的至少一种。 组合物以片剂，胶囊或悬浮液的形式使用。
-
-
-
-
-
-
-
Search Results
8
records
(took 0.023 seconds)
